Iradimed Announces Quarterly Results

IRADIMED CORPORATION (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2025. The Company boasts a status a leader in developing innovative magnetic resonance imaging compatible medical devices. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump system and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.Said CEO Roger Susi, "We are excited to begin 2025 with our fifteenth consecutive quarter of record revenue, achieving $19.5 million in the first quarter, an 11% increase year-over-year. This impressive top-line performance, coupled with a 16% rise year-over-year in diluted EPS, highlights the sustained demand for our innovative products and our team's dedication to operational excellence. “We are also pleased to maintain our quarterly cash dividend at $0.17 per share, underscoring our commitment to delivering value to our shareholders. With our new manufacturing facility on track for completion in July 2025, we are well-positioned to support our planned growth and build upon the momentum of our strong first quarter performance.” Susi continued, “For the second quarter of 2025 financial guidance, we expect revenue of $19.7 million to $19.9 million, GAAP diluted earnings per share of $0.37 to $0.40, and non-GAAP diluted earnings per share of $0.41 to $0.44. IRMD shares closed Friday trading at $53.47.